Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Stich

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Toxins|November 10, 2011
Staphylococcal superantigen (TSST-1) mutant analysis reveals that t cell activation is required for biological effects in the rabbit including the cytokine stormNorbert Stich, Martina Waclavicek, Nina Model, et al.
Journal of Leukocyte Biology|October 17, 2008
Analysis of the early response to TSST-1 reveals Vbeta-unrestricted extravasation, compartmentalization of the response, and unresponsiveness but not anergy to TSST-1Martina Waclavicek, Norbert Stich, Ingrid Rappan, et al.
Journal of Nanoscience and Nanotechnology|April 29, 2004
Tuning the setup of sputter-coated multilayers in nanocluster-based signal-enhancing biochips for optimal performance in protein and DNA assaysViatcheslav Matyushin, Arminder Gandhum, Norbert Stich, et al.
Journal of Nanoscience and Nanotechnology|August 12, 2003
Phage display antibody-based proteomic device using resonance-enhanced detectionNorbert Stich, Arminder Gandhum, Viatcheslav Matyushin, et al.
Toxins|October 7, 2020
High Titer Persistent Neutralizing Antibodies Induced by TSST-1 Variant Vaccine Against Toxic Shock Cytokine StormAndreas Roetzer, Norbert Stich, Nina Model, et al.
Toxins|June 3, 2014
Toxic shock syndrome toxin-1-mediated toxicity inhibited by neutralizing antibodies late in the course of continual in vivo and in vitro exposureNorbert Stich, Nina Model, Aysen Samstag, et al.
The Lancet. Infectious Diseases|June 15, 2016
Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trialMichael Schwameis, Bernhard Roppenser, Christa Firbas, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Toxins|November 10, 2011
Staphylococcal superantigen (TSST-1) mutant analysis reveals that t cell activation is required for biological effects in the rabbit including the cytokine stormNorbert Stich, Martina Waclavicek, Nina Model, et al.
Journal of Leukocyte Biology|October 17, 2008
Analysis of the early response to TSST-1 reveals Vbeta-unrestricted extravasation, compartmentalization of the response, and unresponsiveness but not anergy to TSST-1Martina Waclavicek, Norbert Stich, Ingrid Rappan, et al.
Journal of Nanoscience and Nanotechnology|April 29, 2004
Tuning the setup of sputter-coated multilayers in nanocluster-based signal-enhancing biochips for optimal performance in protein and DNA assaysViatcheslav Matyushin, Arminder Gandhum, Norbert Stich, et al.
Journal of Nanoscience and Nanotechnology|August 12, 2003
Phage display antibody-based proteomic device using resonance-enhanced detectionNorbert Stich, Arminder Gandhum, Viatcheslav Matyushin, et al.
Toxins|October 7, 2020
High Titer Persistent Neutralizing Antibodies Induced by TSST-1 Variant Vaccine Against Toxic Shock Cytokine StormAndreas Roetzer, Norbert Stich, Nina Model, et al.
Toxins|June 3, 2014
Toxic shock syndrome toxin-1-mediated toxicity inhibited by neutralizing antibodies late in the course of continual in vivo and in vitro exposureNorbert Stich, Nina Model, Aysen Samstag, et al.
The Lancet. Infectious Diseases|June 15, 2016
Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trialMichael Schwameis, Bernhard Roppenser, Christa Firbas, et al.
Pageof 1